Aspen Neuroscience closed a $115 million Series C to advance its autologous iPSC-derived cell therapy ANPD001 and expand manufacturing. The company said the financing will accelerate clinical development, fund scaling of its personalized manufacturing platform and support pipeline expansion into other neurological indications. Aspen highlighted recent clinical milestones including dosing in its Phase I/IIa study (NCT06344026) and six-month safety/efficacy signals from early cohorts. The cash infusion aims to solve a common bottleneck for personalized cell therapies—manufacturing at scale—and the company plans to integrate machine learning and genomics to standardize product quality across individualized lots. Aspen noted its approach avoids broad immunosuppression by using autologous cells, positioning ANPD001 as a potentially disease-modifying option for Parkinson’s disease. Investors framed the round as validation of cell therapy manufacturing and clinical progress.